Synopsis
0
VMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Polymyxin B, Sulfate (salt)
2. 1405-20-5
3. Polymixin B Sulphate
4. Ks-1428
5. Pmb
6. Akos025392172
7. Polymyxin B Sulfate, Bacillus Polymyxa
8. M02428
9. Polymyxin B Sulfate (1404-26-8 Free Base)
10. 405p205
Molecular Weight | 1301.6 g/mol |
---|---|
Molecular Formula | C56H100N16O17S |
Hydrogen Bond Donor Count | 20 |
Hydrogen Bond Acceptor Count | 22 |
Rotatable Bond Count | 29 |
Exact Mass | 1300.71730696 g/mol |
Monoisotopic Mass | 1300.71730696 g/mol |
Topological Polar Surface Area | 574 Ų |
Heavy Atom Count | 90 |
Formal Charge | 0 |
Complexity | 2240 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 12 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Polymyxin b sulfate |
Drug Label | Polymyxin B for Injection, USP is one of a group of basic polypeptide antibiotics derived from B polymyxa (B aerosporous). Polymyxin B sulfate is the sulfate salt of Polymyxins B1 and B2, which are produced by the growth of Bacillus polymyxa (Prazmow... |
Active Ingredient | Polymyxin b sulfate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 500,000 u base/vial |
Market Status | Prescription |
Company | X Gen Pharms; Xellia Pharms Aps; Fresenius Kabi Usa; Eurohlth Intl |
2 of 2 | |
---|---|
Drug Name | Polymyxin b sulfate |
Drug Label | Polymyxin B for Injection, USP is one of a group of basic polypeptide antibiotics derived from B polymyxa (B aerosporous). Polymyxin B sulfate is the sulfate salt of Polymyxins B1 and B2, which are produced by the growth of Bacillus polymyxa (Prazmow... |
Active Ingredient | Polymyxin b sulfate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 500,000 u base/vial |
Market Status | Prescription |
Company | X Gen Pharms; Xellia Pharms Aps; Fresenius Kabi Usa; Eurohlth Intl |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23997
Submission : 2010-07-02
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-09-29
Pay. Date : 2013-12-11
DMF Number : 23876
Submission : 2010-05-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13199
Submission : 1998-04-30
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-11-20
Pay. Date : 2013-11-08
DMF Number : 22030
Submission : 2008-10-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35892
Submission : 2021-07-08
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31587
Submission : 2017-03-15
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21244
Submission : 2008-01-09
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2012-11-08
Pay. Date : 2012-10-31
DMF Number : 14187
Submission : 1999-06-10
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2012-11-08
Pay. Date : 2012-10-31
DMF Number : 13536
Submission : 1998-09-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28616
Submission : 2014-09-08
Status : Active
Type : II
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
About the Company : Established in 1982, ChemWerth is a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company. ChemWerth offers cGMP-quality APIs ...
About the Company : Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...
About the Company : Pharm-Rx has earned an outstanding reputation since its establishment in 1991, serving as a reputable importer and distributor of active ingredients to the pharmaceutical, nutritio...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...
About the Company : Fishfa Biogenics, a division of Fishfa Rubbers Ltd., is a leading manufacturer and supplier of high-quality biological APIs. With GLP labs and WHO-GMP-certified facilities, Fishfa ...
About the Company : ALP Pharm began to manufacture some APIs in the partner's facilities in 2007. Some of our APIs have been approved by EDQM and US FDA. Our professional regulatory compliance experts...
About the Company : Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine c...
About the Company : Established in 2010, Mac-Chem is a NMM Group company. Mac-Chem is focused on oncology and other niche specialty APIs. It supplies quality APIs to the top 15 oncology players in Ind...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info : DISCN
Registration Country : USA
NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE
Brand Name : POLY-PRED
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : EQ 0.35% BASE;10,000 UNITS/ML;0.5%
Packaging :
Approval Date : 1982-01-01
Application Number : 50081
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE
Brand Name : POLYTRIM
Dosage Form : SOLUTION/DROPS;OPHTHALMIC
Dosage Strength : 10,000 UNITS/ML;EQ 1MG BASE/ML
Packaging :
Approval Date : 1988-10-20
Application Number : 50567
Regulatory Info : DISCN
Registration Country : USA
Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Lyophilised Injection
Dosage Strength : 500000IU
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : DISCN
Registration Country : USA
GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Brand Name : NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN
Dosage Form : SOLUTION/DROPS;OPHTHALMIC
Dosage Strength : 0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML
Packaging :
Approval Date : 1982-08-31
Application Number : 62383
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Brand Name : DEXASPORIN
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML
Packaging :
Approval Date : 1983-05-18
Application Number : 62428
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Brand Name : NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE
Dosage Form : OINTMENT;OPHTHALMIC
Dosage Strength : 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM
Packaging :
Approval Date : 1994-07-25
Application Number : 64063
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Generic
Registration Country : South Korea
Dexamethasone; Neomycin Sulfate; Polymyxin B
Brand Name : NEODEX
Dosage Form : EYE OINTMENT
Dosage Strength : 1MG/G; 3.5MG/G; 6000IU/G
Packaging : 3.5g /Tubes
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Korea
Regulatory Info : DISCN
Registration Country : USA
HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Brand Name : PEDIOTIC
Dosage Form : SUSPENSION/DROPS;OTIC
Dosage Strength : 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML
Packaging :
Approval Date : 1987-09-29
Application Number : 62822
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info :
Registration Country : Canada
Brand Name : SANDOZ POLYTRIMETHOPRIM
Dosage Form : SOLUTION
Dosage Strength : 10000UNIT/ML
Packaging : 10ML
Approval Date :
Application Number : 2239234
Regulatory Info :
Registration Country : Canada
Regulatory Info : RX
Registration Country : USA
POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE
Brand Name : TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE
Dosage Form : SOLUTION/DROPS;OPHTHALMIC
Dosage Strength : 10,000 UNITS/ML;EQ 1MG BASE/ML
Packaging :
Approval Date : 2024-08-05
Application Number : 211572
Regulatory Info : RX
Registration Country : USA
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Brand Name : Expansorb® PLA / PEG
Application : Parenteral
Excipient Details : Expansorb® PLA?/PEG? polymers are used as functional excipients in injectable formulations for controlled & slow drug release with a single injection.
Pharmacopoeia Ref : N/A
Technical Specs : Classic and ultrapure LMP
Ingredient(s) : Poly lactic acid
Dosage Form : Cream / Lotion / Ointment, Emulsion, Gel, Injectable / Parenteral, Suspension, Tablet
Grade : Parenteral, Oral, Topical
Category : Emulsifying Agents, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Category : Parenteral, Thickeners and Stabilizers
Brand Name : Expansorb® PLGA / PEG
Application : Parenteral
Excipient Details : Expansorb® PLGA? / PEG copolymers are used as functional excipients in single dose injections for controlled and slow drug release (weeks to months).
Pharmacopoeia Ref : N/A
Technical Specs : Classic and ultrapure LMP
Ingredient(s) : Poly-DL-Lactic-co-Glycolic Acid
Dosage Form : Cream / Lotion / Ointment, Emulsion, Injectable / Parenteral, Softgels, Tablet
Grade : Oral, Topical, Parenteral
Category : Film Formers & Plasticizers, Parenteral, Topical
Dosage Form : Capsule, Cream / Lotion / Ointment, Emulsion, Gel, Injectable / Parenteral, Suspension, Tablet
Grade : Parenteral, Oral, Topical
Category : Emulsifying Agents, Film Formers & Plasticizers, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Application : Emulsifying Agents, Film Formers & Plasticizers, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Excipient Details : Polysorbate 80 is used as a plasticizer, solubilizer, emulsifier, surfactant, and suspension stabilizer. It is also used in parenteral products.
Dosage Form : Capsule, Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Solution, Suspension, Tablet
Grade : Parenteral, Oral, Topical
Category : Emulsifying Agents, Film Formers & Plasticizers, Parenteral, Solubilizers, Thickeners and Stabilizers, Topical
Application : Emulsifying Agents, Film Formers & Plasticizers, Parenteral, Solubilizers, Thickeners and Stabilizers, Topical
Excipient Details : Poloxamer 188 is used as a solubilizer, emulsifier, stabilizer in parenteral, OSDs & topical formulations such as creams, gels & lotions.
Pharmacopoeia Ref : ChP/USP/EP
Technical Specs : Oxyethylene unit: 75%-85%, Oxypropylene unit: 25%-30%
Ingredient(s) : Poloxamer 188
Dosage Form : Cream / Lotion / Ointment, Emulsion, Injectable / Parenteral
Grade : Topical, Parenteral
Category : Emulsifying Agents, Parenteral, Solubilizers, Surfactant & Foaming Agents, Topical
Dosage Form : Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Softgels
Grade : Parenteral, Oral, Topical
Category : Film Formers & Plasticizers, Parenteral, Thickeners and Stabilizers, Topical
Application : Parenteral
Excipient Details : Squalene is used as a antioxidant, Influenza vaccine adjuvant, and core ingredient in MF59 emulsions.
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Polymyxin B Sulfate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Polymyxin B Sulfate, including repackagers and relabelers. The FDA regulates Polymyxin B Sulfate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Polymyxin B Sulfate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Polymyxin B Sulfate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Polymyxin B Sulfate supplier is an individual or a company that provides Polymyxin B Sulfate active pharmaceutical ingredient (API) or Polymyxin B Sulfate finished formulations upon request. The Polymyxin B Sulfate suppliers may include Polymyxin B Sulfate API manufacturers, exporters, distributors and traders.
click here to find a list of Polymyxin B Sulfate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Polymyxin B Sulfate DMF (Drug Master File) is a document detailing the whole manufacturing process of Polymyxin B Sulfate active pharmaceutical ingredient (API) in detail. Different forms of Polymyxin B Sulfate DMFs exist exist since differing nations have different regulations, such as Polymyxin B Sulfate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Polymyxin B Sulfate DMF submitted to regulatory agencies in the US is known as a USDMF. Polymyxin B Sulfate USDMF includes data on Polymyxin B Sulfate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Polymyxin B Sulfate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Polymyxin B Sulfate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Polymyxin B Sulfate Drug Master File in Japan (Polymyxin B Sulfate JDMF) empowers Polymyxin B Sulfate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Polymyxin B Sulfate JDMF during the approval evaluation for pharmaceutical products. At the time of Polymyxin B Sulfate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Polymyxin B Sulfate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Polymyxin B Sulfate Drug Master File in Korea (Polymyxin B Sulfate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Polymyxin B Sulfate. The MFDS reviews the Polymyxin B Sulfate KDMF as part of the drug registration process and uses the information provided in the Polymyxin B Sulfate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Polymyxin B Sulfate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Polymyxin B Sulfate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Polymyxin B Sulfate suppliers with KDMF on PharmaCompass.
A Polymyxin B Sulfate CEP of the European Pharmacopoeia monograph is often referred to as a Polymyxin B Sulfate Certificate of Suitability (COS). The purpose of a Polymyxin B Sulfate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Polymyxin B Sulfate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Polymyxin B Sulfate to their clients by showing that a Polymyxin B Sulfate CEP has been issued for it. The manufacturer submits a Polymyxin B Sulfate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Polymyxin B Sulfate CEP holder for the record. Additionally, the data presented in the Polymyxin B Sulfate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Polymyxin B Sulfate DMF.
A Polymyxin B Sulfate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Polymyxin B Sulfate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Polymyxin B Sulfate suppliers with CEP (COS) on PharmaCompass.
A Polymyxin B Sulfate written confirmation (Polymyxin B Sulfate WC) is an official document issued by a regulatory agency to a Polymyxin B Sulfate manufacturer, verifying that the manufacturing facility of a Polymyxin B Sulfate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Polymyxin B Sulfate APIs or Polymyxin B Sulfate finished pharmaceutical products to another nation, regulatory agencies frequently require a Polymyxin B Sulfate WC (written confirmation) as part of the regulatory process.
click here to find a list of Polymyxin B Sulfate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Polymyxin B Sulfate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Polymyxin B Sulfate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Polymyxin B Sulfate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Polymyxin B Sulfate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Polymyxin B Sulfate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Polymyxin B Sulfate suppliers with NDC on PharmaCompass.
Polymyxin B Sulfate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Polymyxin B Sulfate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Polymyxin B Sulfate GMP manufacturer or Polymyxin B Sulfate GMP API supplier for your needs.
A Polymyxin B Sulfate CoA (Certificate of Analysis) is a formal document that attests to Polymyxin B Sulfate's compliance with Polymyxin B Sulfate specifications and serves as a tool for batch-level quality control.
Polymyxin B Sulfate CoA mostly includes findings from lab analyses of a specific batch. For each Polymyxin B Sulfate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Polymyxin B Sulfate may be tested according to a variety of international standards, such as European Pharmacopoeia (Polymyxin B Sulfate EP), Polymyxin B Sulfate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Polymyxin B Sulfate USP).
LOOKING FOR A SUPPLIER?